Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
Titel:
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
Auteur:
Martín, M. Lluch, A. Seguí, M.A. Ruiz, A. Ramos, M. Adrover, E. Rodríguez-Lescure, Á. Grosse, R. Calvo, L. Fernandez-Chacón, C. Roset, M. Antón, A. Isla, D. del Prado, P. Martínez Iglesias, L. Zaluski, J. Arcusa, A. López-Vega, J.M. Muñoz, M. Mel, J.R.